彩神VI·(中国)官方网站

News Center

XLifeSc Announces that Axis Receives FDA Clearance for TCR-T Cell Therapy IND to Initiate Clinical Trials in the USA
FDA Acceptance for Filing of U.S. NDA for Oral Paclitaxel and Encequidar in Metastatic Breast Cancer with Priority Review
Guangzhou Xiangxue Pharmaceutical Expands its Strategic Partnership with Athenex Inc. through a Licensing Agreement for the Product Candidates Oral Paclitaxel, Oral Irinotecan, and Tirbanibulin Ointment, in China
XLifes once again named “top 50 biotechnology enterprises” of GAB
Initiation of Phase I Clinical Study in China of KX2-361 Oral by XPH

XLifeSc Announces that Axis Receives FDA Clearance for TCR-T Cell Therapy IND to Initiate Clinical Trials in the USA

FDA Acceptance for Filing of U.S. NDA for Oral Paclitaxel and Encequidar in Metastatic Breast Cancer with Priority Review

Guangzhou Xiangxue Pharmaceutical Expands its Strategic Partnership with Athenex Inc. through a Licensing Agreement for the Product Candidates Oral Paclitaxel, Oral Irinotecan, and Tirbanibulin Ointment, in China

XLifes once again named “top 50 biotechnology enterprises” of GAB

Initiation of Phase I Clinical Study in China of KX2-361 Oral by XPH

ABOUT XPH

XPH Wisdom TCM - The Chinese Solution to Health Care

more ⇀

INDUSTRIAL

Intergration of TCM Resources, new drug R&D, advanced TCM manufacturing, and distribution technology

more ⇀

R & D

Indepth research and development, engaging in proprietary international collablorations

more⇀

800-888-6655 No. 2, Jinfengyuan Road, Science City, Guangzhou Economic and Technological Development Zone 020-22211555: XPH Group; XLifeSc; Pharmaceutical; TCM Resources